Bristol’s Breyanzi Wins Broader FDA Nod, Bringing CAR-T Showdown

The FDA has cleared Bristol Myers’ Breyanzi to treat newly relapsed or refractory large B-cell lymphoma (LBCL). The nod comes less than three months after Yescarta became first CAR-T drug to enter the second-line setting and a little over a year after Breyanzi’s original go-ahead as a third-line therapy.